S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
NASDAQ:LRMR

Larimar Therapeutics (LRMR) Stock Price, News & Analysis

$7.26
+0.06 (+0.83%)
(As of 03/27/2024 ET)
Today's Range
$7.08
$7.46
50-Day Range
$4.26
$13.28
52-Week Range
$2.18
$13.68
Volume
442,161 shs
Average Volume
578,587 shs
Market Capitalization
$463.51 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.33

Larimar Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
124.8% Upside
$16.33 Price Target
Short Interest
Healthy
2.55% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.44mentions of Larimar Therapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
Acquiring Shares
$37.52 M Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.17) to ($1.86) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.30 out of 5 stars

Medical Sector

694th out of 939 stocks

Pharmaceutical Preparations Industry

324th out of 435 stocks

LRMR stock logo

About Larimar Therapeutics Stock (NASDAQ:LRMR)

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is headquartered in Bala Cynwyd, Pennsylvania.

LRMR Stock Price History

LRMR Stock News Headlines

The Small Biotech with a BIG Cancer Solution
There's a new cancer treatment so precise, it's been called a "smart bomb." One that can deliver a toxic payload directly to tumors while bypassing healthy cells.
LRMR Apr 2024 10.000 call
Larimar: Q4 Earnings Snapshot
Recap: Larimar Therapeutics Q4 Earnings
The Small Biotech with a BIG Cancer Solution
There's a new cancer treatment so precise, it's been called a "smart bomb." One that can deliver a toxic payload directly to tumors while bypassing healthy cells.
LRMR Mar 2024 17.500 call
LRMR Apr 2024 10.000 put
LRMR Mar 2024 25.000 call
LRMR Mar 2024 15.000 put
See More Headlines
Receive LRMR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Larimar Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/12/2021
Today
3/28/2024
Next Earnings (Estimated)
5/20/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:LRMR
Fax
N/A
Employees
26
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$16.33
High Stock Price Target
$25.00
Low Stock Price Target
$10.00
Potential Upside/Downside
+124.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-36,950,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.86 per share

Miscellaneous

Free Float
61,057,000
Market Cap
$463.51 million
Optionable
Optionable
Beta
0.95
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Dr. Carole S. Ben-Maimon M.D. (Age 65)
    CEO, President & Director
    Comp: $845.63k
  • Mr. Michael Celano CPA (Age 65)
    Secretary & CFO
    Comp: $562.62k
  • Mr. John Berman
    Vice President of Finance & Administration
  • Ms. Jennifer Spokes Johansson
    Vice President of Legal & Compliance
  • Dr. Russell G. Clayton Sr. (Age 63)
    D.O, Chief Medical Officer
  • Dr. Gopi Shankar M.B.A. (Age 53)
    Ph.D., Chief Development Officer
  • Mr. Francis Michael Conway CPA
    VP & Controller

LRMR Stock Analysis - Frequently Asked Questions

Should I buy or sell Larimar Therapeutics stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Larimar Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" LRMR shares.
View LRMR analyst ratings
or view top-rated stocks.

What is Larimar Therapeutics' stock price target for 2024?

4 brokers have issued twelve-month price objectives for Larimar Therapeutics' stock. Their LRMR share price targets range from $10.00 to $25.00. On average, they expect the company's stock price to reach $16.33 in the next twelve months. This suggests a possible upside of 124.8% from the stock's current price.
View analysts price targets for LRMR
or view top-rated stocks among Wall Street analysts.

How have LRMR shares performed in 2024?

Larimar Therapeutics' stock was trading at $4.55 at the beginning of 2024. Since then, LRMR stock has increased by 59.7% and is now trading at $7.2650.
View the best growth stocks for 2024 here
.

Are investors shorting Larimar Therapeutics?

Larimar Therapeutics saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 1,630,000 shares, an increase of 221.6% from the February 29th total of 506,800 shares. Based on an average trading volume of 570,900 shares, the days-to-cover ratio is presently 2.9 days.
View Larimar Therapeutics' Short Interest
.

When is Larimar Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our LRMR earnings forecast
.

How were Larimar Therapeutics' earnings last quarter?

Larimar Therapeutics, Inc. (NASDAQ:LRMR) announced its earnings results on Friday, November, 12th. The company reported ($0.92) EPS for the quarter, missing the consensus estimate of ($0.64) by $0.28.

Who are Larimar Therapeutics' major shareholders?

Larimar Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Blue Owl Capital Holdings LP (7.78%), Verition Fund Management LLC (6.40%), Vanguard Group Inc. (3.31%), Vanguard Group Inc. (3.31%), Opaleye Management Inc. (1.42%) and Point72 Asset Management L.P. (1.03%). Insiders that own company stock include Frank E Thomas, James E Flynn, Joseph Truitt, Michael Celano and Thomas Edward Hamilton.
View institutional ownership trends
.

How do I buy shares of Larimar Therapeutics?

Shares of LRMR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:LRMR) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners